- Home
- ICCM vs XGN Comparison
ICCM vs XGN Comparison
Compare ICCM & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- XGN
- Stock Information
- Founded
- ICCM 2006
- XGN 2002
- Country
- ICCM Israel
- XGN United States
- Employees
- ICCM N/A
- XGN N/A
- Industry
- ICCM
- XGN Medical Specialities
- Sector
- ICCM
- XGN Health Care
- Exchange
- ICCM Nasdaq
- XGN Nasdaq
- Market Cap
- ICCM 72.4M
- XGN 72.3M
- IPO Year
- ICCM N/A
- XGN 2019
- Fundamental
- Price
- ICCM $1.21
- XGN $3.96
- Analyst Decision
- ICCM Strong Buy
- XGN Strong Buy
- Analyst Count
- ICCM 2
- XGN 2
- Target Price
- ICCM $2.70
- XGN $7.50
- AVG Volume (30 Days)
- ICCM 441.2K
- XGN 197.2K
- Earning Date
- ICCM 11-26-2024
- XGN 11-12-2024
- Dividend Yield
- ICCM N/A
- XGN N/A
- EPS Growth
- ICCM N/A
- XGN N/A
- EPS
- ICCM N/A
- XGN N/A
- Revenue
- ICCM $3,671,000.00
- XGN $55,751,000.00
- Revenue This Year
- ICCM $10.03
- XGN $6.81
- Revenue Next Year
- ICCM $62.68
- XGN $17.72
- P/E Ratio
- ICCM N/A
- XGN N/A
- Revenue Growth
- ICCM 26.02
- XGN 8.00
- 52 Week Low
- ICCM $0.48
- XGN $1.30
- 52 Week High
- ICCM $1.57
- XGN $6.22
- Technical
- Relative Strength Index (RSI)
- ICCM 60.15
- XGN 54.15
- Support Level
- ICCM $1.16
- XGN $2.76
- Resistance Level
- ICCM $1.27
- XGN $4.20
- Average True Range (ATR)
- ICCM 0.10
- XGN 0.47
- MACD
- ICCM -0.02
- XGN 0.04
- Stochastic Oscillator
- ICCM 41.64
- XGN 82.74
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.